Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INS37217 Nasal Spray
INS37217 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS37217 Nasal Spray | DRUG | - |
Inclusion Criteria: * Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing. * Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies. * Have not sta...
INS37217 is being developed for the treatment of perennial allergic rhinitis, a year-round allergic condition of the nasal passages. It is an investigational small molecule studied in a Phase 2 clinical trial that enrolled 630 participants with this condition. It is not approved for commercial use.
INS37217 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 2 clinical study of the drug in perennial allergic rhinitis. The compound is an investigational asset within the company's respiratory therapeutic area.
INS37217 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The completed study was randomized and double blind, and it enrolled 630 participants with perennial allergic rhinitis. The drug remains investigational and has not been approved.
INS37217 has been studied in one clinical trial, NCT00210015, titled A Study in Subjects With Perennial Allergic Rhinitis. That Phase 2 trial is completed and enrolled 630 participants. It was randomized and double blind, with an uncontrolled design, meaning participants were not compared against a placebo or active comparator arm.
Yes, INS37217 Nasal Spray is another name for INS37217. Both names refer to the same investigational small molecule developed by Merck & Company, Inc. for perennial allergic rhinitis. Readers searching for either name are looking at the same Phase 2 asset.